[HTML][HTML] PCI strategies in patients with acute myocardial infarction and cardiogenic shock

…, J Stepinska, K Oldroyd, P Serpytis… - … England Journal of …, 2017 - Mass Medical Soc
Background In patients who have acute myocardial infarction with cardiogenic shock, early
revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) …

[HTML][HTML] Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

…, P Ponikowski, FJA Ramires, P Serpytis… - … England Journal of …, 2021 - Mass Medical Soc
Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

[HTML][HTML] One-year outcomes after PCI strategies in cardiogenic shock

…, J Stepinska, K Oldroyd, P Serpytis… - … England Journal of …, 2018 - Mass Medical Soc
Background Among patients with acute myocardial infarction, cardiogenic shock, and
multivessel coronary artery disease, the risk of a composite of death from any cause or severe …

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

…, M Metra, V Mitrovic, P Ponikowski, P Serpytis… - The Lancet, 2016 - thelancet.com
Background Impaired contractility is a feature of heart failure with reduced ejection fraction.
We assessed the pharmacokinetics and effects on cardiac function and structure of the …

Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated …

…, JJ Piek, J Stepinska, K Oldroyd, P Serpytis… - American heart …, 2016 - Elsevier
… Piek MD, PhD c , Janina Stepinska MD d , Keith Oldroyd MD e , Pranas Serpytis MD f , Gilles
Montalescot MD g , Marko Noc MD h , Kurt Huber MD i , Georg Fuernau MD a b , Suzanne …

Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of …

…, G Bajraktari, H Al-Farhan, P Šerpytis… - European heart …, 2021 - academic.oup.com
Aims The aim of this study was to determine the contemporary use of reperfusion therapy in
the European Society of Cardiology (ESC) member and affiliated countries and adherence …

[HTML][HTML] Gender-based differences in anxiety and depression following acute myocardial infarction

P Serpytis, P Navickas, L Lukaviciute… - Arquivos brasileiros de …, 2018 - SciELO Brasil
Background: Among patients with heart disease, depression and anxiety disorders are
highly prevalent and persistent. Both depression and anxiety play a significant role in …

Editor's Choice-Acute Cardiovascular Care Association position paper on intensive cardiovascular care units: an update on their definition, structure, organisation and …

…, S Price, R Rokyta, F Roubille, P Serpytis… - … Heart Journal: Acute …, 2018 - academic.oup.com
Acute cardiovascular care has progressed considerably since the last position paper was
published 10 years ago. It is now a well-defined, complex field with demanding …

[HTML][HTML] Cardiac shock-wave therapy in the treatment of coronary artery disease: systematic review and meta-analysis

…, I Butkuvienė, B Petrauskienė, P Šerpytis… - Cardiovascular …, 2017 - Springer
Aim To systematically review currently available cardiac shock-wave therapy (CSWT) studies
in humans and perform meta-analysis regarding anti-anginal efficacy of CSWT. Methods …

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials

…, P Ponikowski, FJA Ramires, P Serpytis… - European journal of …, 2020 - Wiley Online Library
Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in …